Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

Exclusion Criteria

• •1. Patients with acute or subacute infection (such as fever, cough, urgency, dysuria, abdominal pain, diarrhea and skin infection wounds, etc.) within 2 weeks before screening, or acute or chronic infection within 4 weeks before screening history, and receiving systemic anti-infective treatment;
• •2. Those who have a history of tuberculosis infection in the past;
• •3. The results of physical examination, vital sign measurement, laboratory examination, electrocardiogram, chest X-ray, etc. are abnormal and have clinical significance;
• •4. Those who are known to be allergic to monoclonal antibody drugs or excipients of MG-ZG122 injection, or food allergies judged by the investigator to be unsuitable to participate in the researcher;
• •5. Those who have been vaccinated within 1 month before screening or plan to be vaccinated during the study;
• •6. Those who have used any prescription drugs within 2 weeks before administration, those who have used non-prescription drugs or traditional Chinese medicines within 1 week before administration, or those who are expected to use prescription drugs, non-prescription drugs and traditional Chinese medicines during the study period;
• •7. Those who have received any research non-biological agents within 5 half-lives (if known) or within 3 months (whichever is longer) before administration, or have participated in other clinical trials or plan to participate in other clinical trials during the study period. clinical trial subjects;
• •8. Those who have special requirements for diet or cannot accept a unified diet;
• •9. Women who are lactating and pregnant, or female volunteers of childbearing age have a positive serum pregnancy test;